01 / Date the information
SuperHealthy Rx's retrieved offer lists compounded semaglutide at $85 monthly and tirzepatide at $135. The page still displayed Labor Day promotion language when checked October 5, 2026. Treat the figures as an observation from that page and confirm the actual checkout offer. We have not independently established when the promotion ends.
02 / Separate the bundle from the decision
The offer combines medical review, medication and shipping without an additional membership fee. Automatic refills are described as optional. Those statements concern the service arrangement. They do not decide whether a medicine should be prescribed, whether a compounded preparation meets a particular medical need or whether continued treatment is appropriate.
03 / Ask for specific identities
The page refers to MD Integrations and U.S. licensed pharmacies. A network reference does not name the individual professional or pharmacy involved in your care. Ask for those details and the route for confirming the product label. FDA's concerns about unapproved GLP-1 products make precise identification more useful than a broad reassurance.
04 / Clarify the instruction pathway
Before using any prescribed product, establish where its instructions come from and who will resolve a discrepancy. A provider's advertisement should not be used as a dosing reference. Compounded medicines are not FDA-approved, and instructions for a different brand or presentation should not be assumed to apply.
The publisher selected SuperHealthy for promotional position two. Links may provide compensation. The Clinical Literacy Desk has not received care through the service or tested its clinical follow-up. Our role is to identify questions that make the public offer more understandable, while leaving individual medical decisions with the responsible licensed professional.
Source notes
Checked October 5, 2026. Provider pages document advertised terms. Study summaries identify the scope of our review.
- SuperHealthy Rx — GLP-1 offerProvider promotion
- FDA — compounding questions and answersCompounded-product context
- FDA — concerns with unapproved GLP-1 productsMedication safety context